Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Insights

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

- PMLiVE

Rise in cancer therapy costs ‘unsustainable’ says oncologist

Leonard Saltz made the claims in his keynote presentation at ASCO

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

UK Life Sciences Strategy - one year on

Express Scripts pushes for pay-for-performance in cancer

States it is the only way to fund the growing cost of cancer care

- PMLiVE

Amgen’s immuno-oncology drug scores in skin cancer

Firm hoping its novel treatment will be on the market be the end of this year

- PMLiVE

AZ escapes censure over cancer tweet

Firm did not breach UK’s Code of Practice over survival statistics post

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

Boehringer Ingelheim headquarters

Boehringer teams up with Eureka on intracellular cancer targets

Alliance will use Eureka technology to identify antibodies recognising relevant proteins

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

- PMLiVE

Havas Lynx Group bolsters senior ranks

Agency sees three new appointments at the top of its organisation

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links